Answers are grounded in this paper and cite their sources.
Our findings reveal that BRD4 serves as a novel and critical mediator underlying tumorigenesis and a robust prognostic biomarker in HNSCC. Therapeutic targeting of BRD4 represents a potent and promising strategy against HNSCC.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: